Denali Therapeutics (DNLI) Assets (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Assets of $1.3 billion for Q1 2026, little changed year-over-year from $1.3 billion in Q1 2025, and up 10.58% quarter-over-quarter from $1.1 billion in Q4 2025.
Denali Therapeutics (DNLI) Assets (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Assets for 10 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets changed 0.42% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (changed 0.42% YoY), while the FY2025 annual figure was $1.1 billion, down 16.69% from the prior year.
- Assets grew to $1.3 billion in Q1 2026 per DNLI's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Assets topped out at $1.6 billion in Q1 2024 and bottomed at $1.1 billion in Q3 2025.
- Historically, Assets has averaged $1.3 billion across 5 years, with a median of $1.3 billion in 2022.
- Annual changes were most pronounced in 2024 — Assets gained 19.09% — and 2025, when it declined 27.4%.
- Denali Therapeutics' Assets stood at $1.5 billion in 2022, then retreated by 20.98% to $1.2 billion in 2023, then increased by 19.09% to $1.4 billion in 2024, then declined by 16.69% to $1.1 billion in 2025, then advanced by 10.58% to $1.3 billion in 2026.
- Business Quant data shows DNLI's Assets at $1.3 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 1.16 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Bn |
| Mar 31, 2026 | 1.27 Bn |
| Dec 31, 2025 | 1.14 Bn |
| Sep 30, 2025 | 1.06 Bn |
| Jun 30, 2025 | 1.17 Bn |
| Mar 31, 2025 | 1.27 Bn |
| Dec 31, 2024 | 1.37 Bn |
| Sep 30, 2024 | 1.45 Bn |
| Jun 30, 2024 | 1.50 Bn |
| Mar 31, 2024 | 1.58 Bn |
| Dec 31, 2023 | 1.15 Bn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.31 Bn |
| Mar 31, 2023 | 1.41 Bn |
| Dec 31, 2022 | 1.46 Bn |
| Sep 30, 2022 | 1.23 Bn |
| Jun 30, 2022 | 1.29 Bn |
| Mar 31, 2022 | 1.32 Bn |
| Dec 31, 2021 | 1.40 Bn |
| Sep 30, 2021 | 1.45 Bn |